IL301266A - Process for preparing biheteroaryl compounds and their crystalline forms - Google Patents
Process for preparing biheteroaryl compounds and their crystalline formsInfo
- Publication number
- IL301266A IL301266A IL301266A IL30126623A IL301266A IL 301266 A IL301266 A IL 301266A IL 301266 A IL301266 A IL 301266A IL 30126623 A IL30126623 A IL 30126623A IL 301266 A IL301266 A IL 301266A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- solvent
- alkyl
- group
- base
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087109P | 2020-10-02 | 2020-10-02 | |
| PCT/US2021/053005 WO2022072721A1 (en) | 2020-10-02 | 2021-09-30 | Process for the preparation of biheteroaryl compounds and crystal forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301266A true IL301266A (en) | 2023-05-01 |
Family
ID=78599176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301266A IL301266A (en) | 2020-10-02 | 2021-09-30 | Process for preparing biheteroaryl compounds and their crystalline forms |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230312473A1 (enExample) |
| EP (1) | EP4222154A1 (enExample) |
| JP (1) | JP7805356B2 (enExample) |
| KR (1) | KR20230079123A (enExample) |
| CN (1) | CN116744933A (enExample) |
| AU (1) | AU2021353532A1 (enExample) |
| BR (1) | BR112023005853A2 (enExample) |
| CA (1) | CA3200566A1 (enExample) |
| CL (3) | CL2023000945A1 (enExample) |
| CR (1) | CR20230183A (enExample) |
| IL (1) | IL301266A (enExample) |
| MX (1) | MX2023003759A (enExample) |
| PE (1) | PE20230781A1 (enExample) |
| SA (1) | SA523440027B1 (enExample) |
| WO (1) | WO2022072721A1 (enExample) |
| ZA (1) | ZA202303449B (enExample) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| AU2003302676A1 (en) | 2002-12-03 | 2004-06-23 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| CN104043126A (zh) | 2009-10-22 | 2014-09-17 | 霍夫曼-拉罗奇有限公司 | 轴突变性的调节 |
| PE20161063A1 (es) * | 2013-05-01 | 2016-10-22 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
-
2021
- 2021-09-30 JP JP2023520162A patent/JP7805356B2/ja active Active
- 2021-09-30 EP EP21806494.7A patent/EP4222154A1/en active Pending
- 2021-09-30 CR CR20230183A patent/CR20230183A/es unknown
- 2021-09-30 MX MX2023003759A patent/MX2023003759A/es unknown
- 2021-09-30 KR KR1020237013971A patent/KR20230079123A/ko not_active Ceased
- 2021-09-30 WO PCT/US2021/053005 patent/WO2022072721A1/en not_active Ceased
- 2021-09-30 AU AU2021353532A patent/AU2021353532A1/en active Pending
- 2021-09-30 CA CA3200566A patent/CA3200566A1/en active Pending
- 2021-09-30 CN CN202180067829.1A patent/CN116744933A/zh active Pending
- 2021-09-30 BR BR112023005853A patent/BR112023005853A2/pt unknown
- 2021-09-30 PE PE2023001333A patent/PE20230781A1/es unknown
- 2021-09-30 IL IL301266A patent/IL301266A/en unknown
-
2023
- 2023-03-09 ZA ZA2023/03449A patent/ZA202303449B/en unknown
- 2023-03-30 CL CL2023000945A patent/CL2023000945A1/es unknown
- 2023-03-31 US US18/194,423 patent/US20230312473A1/en active Pending
- 2023-04-02 SA SA523440027A patent/SA523440027B1/ar unknown
-
2024
- 2024-10-07 CL CL2024003034A patent/CL2024003034A1/es unknown
- 2024-10-07 CL CL2024003032A patent/CL2024003032A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023544037A (ja) | 2023-10-19 |
| US20230312473A1 (en) | 2023-10-05 |
| BR112023005853A2 (pt) | 2023-05-02 |
| ZA202303449B (en) | 2025-04-30 |
| WO2022072721A1 (en) | 2022-04-07 |
| AU2021353532A8 (en) | 2023-05-04 |
| CL2024003034A1 (es) | 2025-02-21 |
| JP7805356B2 (ja) | 2026-01-23 |
| CL2024003032A1 (es) | 2025-02-21 |
| CL2023000945A1 (es) | 2023-09-29 |
| PE20230781A1 (es) | 2023-05-09 |
| AU2021353532A1 (en) | 2023-04-13 |
| CA3200566A1 (en) | 2022-04-07 |
| SA523440027B1 (ar) | 2024-07-31 |
| EP4222154A1 (en) | 2023-08-09 |
| CR20230183A (es) | 2023-06-14 |
| MX2023003759A (es) | 2023-04-24 |
| CN116744933A (zh) | 2023-09-12 |
| KR20230079123A (ko) | 2023-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7603118B2 (ja) | イオンチャネルモジュレーター | |
| JP7739180B2 (ja) | シクロアルキルウレア誘導体 | |
| EP2945938B1 (en) | 3-substituted pyrazoles and use as dlk inhibitors | |
| JP2025520934A (ja) | Ｐｒｍｔ５阻害剤及びその使用 | |
| CN111655682B (zh) | 一种高活性sting蛋白激动剂化合物 | |
| CA3150738A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| IL259421A (en) | Modulators of ror-gamma | |
| AU2017206382C1 (en) | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | |
| IL280856B (en) | 3-Alkyl-4-amino-[0,5,4] bicyclic hydroxamic acids as hdac inhibitors | |
| CA2953177A1 (en) | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain | |
| CN115210233B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CA3230123A1 (en) | Spiro indoline inhibitors of kif18a | |
| AU2018223982A1 (en) | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | |
| IL295393A (en) | P2x3 modulators | |
| IL273606A (en) | Derived ring fused as an A2A receptor inhibitor | |
| KR102537616B1 (ko) | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| CN111727191A (zh) | 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 | |
| CN111704615A (zh) | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 | |
| TW202540125A (zh) | 雙環雜芳基化合物 | |
| KR20130025857A (ko) | 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법 | |
| JP7805356B2 (ja) | ビヘテロアリール化合物およびその結晶形態を調製するための方法 | |
| RU2850261C1 (ru) | Способ получения бигетероарильных соединений и их кристаллических форм | |
| JP7668768B2 (ja) | シクロアルキルウレア誘導体を含有する医薬組成物 | |
| CA2909735C (en) | Tricyclic triazolic compounds as sigma receptors ligands | |
| HK40099799A (zh) | 用於制备双杂芳基化合物及其晶型的方法 |